Expert Point of View: Dean F. Bajorin, MD

Get Permission

“This is the most robust and definitive study ever done to compare clinical and pathologic staging,” stated formal discussant of this study, Dean F. Bajorin, MD, Attending Physician, Memorial Sloan-Kettering Cancer Center, New York, at the Genitourinary Cancers Symposium. “The study found that 42% of patients were understaged clinically, and 46% of T2 tumors were upstaged pathologically,” he said.

“The study implies that we cannot compare overall survival in surgical and nonsurgical series, and we cannot pick the favorable stage T2 tumors. Markers are needed to enhance accuracy. This presents a compelling argument for multimodality therapy and for better understanding of tumor biology,” Dr. Bajorin told listeners. ■

Disclosure: Dr. Bajorin reported no potential conflicts of interest.

Related Articles

Clinical-Pathologic Stage Discrepancy High in Patients with Bladder Cancer Undergoing Surgery

About 48% of all patients with bladder cancer undergoing radical cystectomy have a discrepancy between their clinical stage and pathologic stage, according to the largest study to date to examine this issue. Upstaging after surgery is associated with reduced survival, while downstaging after...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.